Endogenex, Inc.

Other Health CareMedical DevicesType 2 DiabetesClinical-Stage

📍 Plymouth, Minnesota, United States• Founded 2017

StreetZero Signal 72

Be the first to signal interest

About Endogenex, Inc.

Endogenex, Inc. is a clinical-stage medical technology company developing the ReCET System, an endoscopic procedure using non-thermal pulsed electric fields to treat the duodenum for type 2 diabetes patients. The company aims to help restore duodenal health and improve blood glucose control beyond symptom management. Founded in 2017, Endogenex is headquartered in Plymouth, Minnesota, and is advancing pivotal clinical studies toward FDA approval.

LATEST FUNDINGPrivate Placement

$132.4M

Announced 2026-11-06

TOTAL RAISED$163.04M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Endogenex, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2017

HQPlymouth, Minnesota, United States

Industry

Other Health Care

Investors

Mayo Clinic Intuitive Ventures Lumira Ventures Longitude Capital Hatteras Venture Partners Sante Ventures Arboretum Ventures Orlando Health Ventures

Key highlights

Announced $88M Series C in 2024 led by undisclosed strategic investor and existing backers to finish pivotal ReCET trial
Closed $50M Series C extension in 2026 with Arboretum Ventures as new lead to fund FDA path
Developing non-thermal pulsed electric field therapy targeting duodenal dysfunction in type 2 diabetes
CEO Stacey Pugh highlighted funding to address unmet needs beyond GLP-1 and SGLT2 therapies